10824 related articles for article (PubMed ID: 1337321)
1. Modifications of the binding properties of the human VIP receptor of IGR39 cells by sulfhydryl reagents.
Fouchier F; Forget P; Pic P; Marvaldi J; Pichon J
Eur J Cell Biol; 1992 Dec; 59(2):382-8. PubMed ID: 1337321
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved.
Fouchier F; Pichon J; Forget P
Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the vasoactive intestinal peptide receptor in rat submandibular gland: radioligand binding assay in membrane preparations.
Turner JT; Bylund DB
J Pharmacol Exp Ther; 1987 Sep; 242(3):873-81. PubMed ID: 2821229
[TBL] [Abstract][Full Text] [Related]
4. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
[TBL] [Abstract][Full Text] [Related]
5. Effects of thiol-reagents on [3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to rat telencephalic membranes.
Terramani T; Kessler M; Lynch G; Baudry M
Mol Pharmacol; 1988 Aug; 34(2):117-23. PubMed ID: 2901029
[TBL] [Abstract][Full Text] [Related]
6. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
[TBL] [Abstract][Full Text] [Related]
7. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
Martin JM; Luis J; Marvaldi J; Pichon J; Pic P
Eur J Biochem; 1989 Mar; 180(2):435-9. PubMed ID: 2538331
[TBL] [Abstract][Full Text] [Related]
8. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
9. Effects of sulfhydryl modification reagents on the kinase activity of the epidermal growth factor receptor.
Woltjer RL; Staros JV
Biochemistry; 1997 Aug; 36(32):9911-6. PubMed ID: 9245424
[TBL] [Abstract][Full Text] [Related]
10. The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes.
Pineau N; Lelievre V; Goursaud S; Hilairet S; Waschek JA; Janet T; Muller JM
Neuropeptides; 2001 Apr; 35(2):117-26. PubMed ID: 11384207
[TBL] [Abstract][Full Text] [Related]
11. Properties of vasoactive intestinal peptide-receptor interaction in rat liver membranes.
Guerrero JM; Prieto JC; Ramírez-Cárdenas R; Calvo JR; Goberna R
Rev Esp Fisiol; 1981 Mar; 37(1):1-8. PubMed ID: 6113623
[TBL] [Abstract][Full Text] [Related]
12. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site.
Luis J; Martin JM; el Battari A; Reynier M; Marvaldi J; Pichon J
Eur J Biochem; 1989 Mar; 180(2):429-33. PubMed ID: 2538330
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
14. [Autoradiographic localization and characterization of the ocular binding sites of the VIP (vasoactive intestinal peptide) in albino rats and rabbits].
Denis P; Dussaillant M; Elena PP; Nordmann JP; Rostene W; Laroche L
Ophtalmologie; 1990; 4(1):30-2. PubMed ID: 2174530
[TBL] [Abstract][Full Text] [Related]
15. 125I-vasoactive intestinal peptide binding in human kidney.
Charlton BG; Neal DE; Simmons NL
Miner Electrolyte Metab; 1991; 17(6):372-6. PubMed ID: 1823387
[TBL] [Abstract][Full Text] [Related]
16. [Vasoactive intestinal peptide receptor in a human pancreatic carcinoma cell line].
Chen Y
Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):135-7, 12. PubMed ID: 2163737
[TBL] [Abstract][Full Text] [Related]
17. The effects of sulfhydryl-modifying reagents on cholecystokinin-receptor interactions in guinea pig gastric glands.
Ramani N; Praissman M
Endocrinology; 1989 Jun; 124(6):2821-9. PubMed ID: 2721447
[TBL] [Abstract][Full Text] [Related]
18. The effects of ribavirin on the GTP level and the VIP receptor dynamic of human IGR39 cells.
Fouchier F; Forget P; Bellan C; Marvaldi J; Champion S; Pichon J
J Recept Signal Transduct Res; 1996; 16(1-2):39-58. PubMed ID: 8771530
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional analysis of the human vasoactive intestinal peptide receptor glycosylation. Alteration of receptor function by wheat germ agglutinin.
Chochola J; Fabre C; Bellan C; Luis J; Bourgerie S; Abadie B; Champion S; Marvaldi J; el Battari A
J Biol Chem; 1993 Feb; 268(4):2312-8. PubMed ID: 8381403
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibiting N-glycosylation or oligosaccharide processing on vasoactive intestinal peptide receptor binding activity and structure.
el Battari A; Forget P; Fouchier F; Pic P
Biochem J; 1991 Sep; 278 ( Pt 2)(Pt 2):527-33. PubMed ID: 1654885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
